Promethera Biosciences SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Promethera Biosciences SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10881
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Promethera Biosciences SA (Promethera) is a developer of cell therapy products for the treatment of liver diseases. The company provides products which are developed on its proprietary progenitor cell type. It offers products such as promethera hepastem and promethera hepascreen, among others. Promethera provides hepastem which is a therapeutic product, designed to treat liver diseases by allogeneic liver injection of HHALPC. The company also undertakes clinical studies. It develops liver cell-based technologies to bringing therapeutic solutions for patients with acute and chronic liver diseases. The company collaborates with research institutes and pharmaceutical companies for its research activities. Promethera is headquartered in Nivelles, Belgium.

Promethera Biosciences SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Promethera Biosciences SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Promethera Biosciences Acquires Assets of Cytonet 11
Venture Financing 12
Promethera Biosciences Raises USD11 Million in Extended Series C Financing 12
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 14
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 16
Partnerships 17
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 17
Licensing Agreements 18
Lifeliver Enters into Licensing Agreement with Promethera Biosciences 18
Baliopharm Enters Into Licensing Agreement With ApoGbR For Novotarg 19
Debt Offering 20
Promethera Biosciences Raises USD11.4 Million in Private Placement of Bonds 20
Acquisition 21
Promethera Biosciences Acquires Baliopharm 21
Promethera Biosciences SA – Key Competitors 22
Promethera Biosciences SA – Key Employees 23
Promethera Biosciences SA – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Oct 05, 2018: Promethera Biosciences names Mutsuki Takano to Group Chief Financial Officer 25
Apr 06, 2018: Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman of the Board 26
Nov 21, 2017: Promethera Biosciences Provides Update on Executive Management Team 27
Feb 09, 2017: Promethera Biosciences Announces Key Additions to its Executive Management Team 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Key Facts 2
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Promethera Biosciences SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Promethera Biosciences SA, Deals By Therapy Area, 2012 to YTD 2018 8
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Promethera Biosciences Acquires Assets of Cytonet 11
Promethera Biosciences Raises USD11 Million in Extended Series C Financing 12
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 14
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 16
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 17
Lifeliver Enters into Licensing Agreement with Promethera Biosciences 18
Baliopharm Enters Into Licensing Agreement With ApoGbR For Novotarg 19
Promethera Biosciences Raises USD11.4 Million in Private Placement of Bonds 20
Promethera Biosciences Acquires Baliopharm 21
Promethera Biosciences SA, Key Competitors 22
Promethera Biosciences SA, Key Employees 23
Promethera Biosciences SA, Other Locations 24
Promethera Biosciences SA, Subsidiaries 24

List of Figures
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Promethera Biosciences SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Promethera Biosciences SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The SPAR Group Limited:企業の戦略・SWOT・財務情報
    The SPAR Group Limited - Strategy, SWOT and Corporate Finance Report Summary The SPAR Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • BioStem Technologies Inc (BSEM):製薬・医療:M&Aディール及び事業提携情報
    Summary BioStem Technologies Inc. (BioStem Technologies), formerly Caribbean International Holdings Inc., is a life sciences company that discovers, develops and manufactures pharmaceuticals and regenerative medicines. Through its subsidiaries, the company discovers, develops, produces and commercia …
  • Joincare Pharmaceutical Group Industry Co Ltd (600380):製薬・医療:M&Aディール及び事業提携情報
    Summary Joincare Pharmaceutical Group Industry Co Ltd (Joincare Pharma) is a manufacturer and supplier of pharmaceutical products. The company offers healthcare products, bulk prescription products, active pharmaceutical ingredients, OTC products, detection reagents, and food additives. Its healthca …
  • Sanmina Corp (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corp (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Astra Microwave Products Limited:企業の戦略・SWOT・財務分析
    Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report Summary Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Bone Solutions Inc-医療機器分野:企業M&A・提携分析
    Summary Bone Solutions Inc (BSI) is a medical device company that offers orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It offers osteocrete bone graft substitute that provides adhere ligaments and tendons t …
  • Hoya Corporation:企業のM&A・事業提携・投資動向
    Hoya Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hoya Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • AT&T Inc:戦略・SWOT・企業財務分析
    AT&T Inc - Strategy, SWOT and Corporate Finance Report Summary AT&T Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Arch Pharmalabs Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Arch Pharmalabs Ltd (Arch Pharmalabs) is a healthcare products company that offers pharmaceutical ingredients. The company manufactures, develops and markets active APIs and intermediates. It offers products such as docetaxel anhydrous and trihydrate, amlodipine besylate, perindopril erbumin …
  • Kobayashi Pharmaceutical Co Ltd (4967)-製薬・医療分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Planmeca Oy:企業の戦略的SWOT分析
    Planmeca Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mirach Energy Ltd (AWO):石油・ガス:M&Aディール及び事業提携情報
    Summary Mirach Energy Ltd (Mirach Energy), formerly China Petrotech Holdings Ltd is a diversified company. The company operates through its business such as property and construction and oilfield services. Its oilfield services business offers enhanced oil recovery techniques and consultancy service …
  • Novartis Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Novartis Pharmaceuticals Corp (Novartis), a subsidiary of Novartis AG, is a manufacturer of prescription drugs. The company portfolio includes cardio metabolic, ophthalmology, respiratory, neuroscience, immunology and dermatology, oncology, call and gene therapy. It provides medicines such a …
  • Equinor ASA.:企業の戦略・SWOT・財務分析
    Equinor ASA. - Strategy, SWOT and Corporate Finance Report Summary Equinor ASA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …
  • Wotif.com Holdings Limited:企業の戦略・SWOT・財務分析
    Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析
    Summary Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company's product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the tr …
  • Natera Inc (NTRA):企業の製品パイプライン分析2018
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …
  • Brooks MacDonald Group PLC (BRK):企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆